 | • レポートコード：MRC2303E067 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、255ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に7,219.22百万ドルであった世界の細胞免疫療法市場規模が、2022年に9,000.43百万ドルに達し、2027年には27,444.12百万ドルまで年平均24.92%成長すると予測しています。当レポートは、細胞免疫療法の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（CAR T細胞療法、樹状細胞療法、NK細胞療法、TIL療法）分析、疾患別（B細胞悪性腫瘍、肝臓がん、前立腺がん、腎細胞がん）分析、技術タイプ別（サイトカイン＆免疫調節剤、モノクローナル抗体）分析、エンドユーザー別（がん研究所、病院）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめております。なお、当書には、Adaptimmune Therapeutics plc.、Adicet Bio、Apac Biotech Private Limited、AstraZeneca AstraZeneca plc、Atara Biotherapeutics, Inc.、Bristol-Myers Squibb Company、Celyad Oncology SA、Dendreon Pharmaceuticals LLC、F. Hoffmann-La Roche Ltd.、Gilead Sciences, Inc.、GlaxoSmithKline plc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の細胞免疫療法市場規模：種類別 - CAR T細胞療法の市場規模 - 樹状細胞療法の市場規模 - NK細胞療法の市場規模 - TIL療法の市場規模 ・世界の細胞免疫療法市場規模：疾患別 - B細胞悪性腫瘍における市場規模 - 肝臓がんにおける市場規模 - 前立腺がんにおける市場規模 - 腎細胞がんにおける市場規模 ・世界の細胞免疫療法市場規模：技術タイプ別 - サイトカイン＆免疫調節剤の市場規模 - モノクローナル抗体技術の市場規模 ・世界の細胞免疫療法市場規模：エンドユーザー別 - がん研究所における市場規模 - 病院における市場規模 ・世界の細胞免疫療法市場規模：地域別 - 南北アメリカの細胞免疫療法市場規模 アメリカの細胞免疫療法市場規模 カナダの細胞免疫療法市場規模 ブラジルの細胞免疫療法市場規模 ... - アジア太平洋の細胞免疫療法市場規模 日本の細胞免疫療法市場規模 中国の細胞免疫療法市場規模 インドの細胞免疫療法市場規模 韓国の細胞免疫療法市場規模 台湾の細胞免疫療法市場規模 ... - ヨーロッパ/中東/アフリカの細胞免疫療法市場規模 イギリスの細胞免疫療法市場規模 ドイツの細胞免疫療法市場規模 インドの細胞免疫療法市場規模 フランスの細胞免疫療法市場規模 ロシアの細胞免疫療法市場規模 ... - その他地域の細胞免疫療法市場規模 ・競争状況 ・企業情報 |
The Global Cellular Immunotherapy Market size was estimated at USD 7,219.22 million in 2021 and expected to reach USD 9,000.43 million in 2022, and is projected to grow at a CAGR 24.92% to reach USD 27,444.12 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cellular Immunotherapy to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, and TIL Therapy.
Based on Indication, the market was studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
Based on Technology Type, the market was studied across Cytokines & Immunomodulators and Monoclonal Antibodies.
Based on End Use, the market was studied across Cancer Institutes and Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cellular Immunotherapy market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cellular Immunotherapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cellular Immunotherapy Market, including Adaptimmune Therapeutics plc., Adicet Bio, Apac Biotech Private Limited, AstraZeneca AstraZeneca plc, Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Johnson & Johnson Services, Inc., JW CreaGene Co. Ltd, JW therapeutic, Merck KGaA, Novartis AG, Pfizer Inc., and Tessa Therapeutics Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cellular Immunotherapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cellular Immunotherapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cellular Immunotherapy Market?
4. What is the competitive strategic window for opportunities in the Global Cellular Immunotherapy Market?
5. What are the technology trends and regulatory frameworks in the Global Cellular Immunotherapy Market?
6. What is the market share of the leading vendors in the Global Cellular Immunotherapy Market?
7. What modes and strategic moves are considered suitable for entering the Global Cellular Immunotherapy Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of cancer and advanced cell based therapies
5.1.1.2. Favorable government initiatives for cellular therapies R&D
5.1.1.3. Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
5.1.2. Restraints
5.1.2.1. High initial costs of devices and therapies
5.1.3. Opportunities
5.1.3.1. Technological advancements and new products for cellular immunotherapy
5.1.3.2. Increasing approvals of different cell-based immunotherapy drugs
5.1.4. Challenges
5.1.4.1. Product recalls and stringent regulatory approvals
5.2. Cumulative Impact of COVID-19
6. Cellular Immunotherapy Market, by Type
6.1. Introduction
6.2. CAR T Cell Therapy
6.3. Dendritic Cell Therapy
6.4. NK Cell Therapy
6.5. TIL Therapy
7. Cellular Immunotherapy Market, by Indication
7.1. Introduction
7.2. B-cell Malignancies
7.3. Liver Cancer
7.4. Prostate Cancer
7.5. Renal Cell Carcinoma
8. Cellular Immunotherapy Market, by Technology Type
8.1. Introduction
8.2. Cytokines & Immunomodulators
8.3. Monoclonal Antibodies
9. Cellular Immunotherapy Market, by End Use
9.1. Introduction
9.2. Cancer Institutes
9.3. Hospitals
10. Americas Cellular Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cellular Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cellular Immunotherapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Adaptimmune Therapeutics plc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Adicet Bio
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Apac Biotech Private Limited
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. AstraZeneca AstraZeneca plc
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Atara Biotherapeutics, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bristol-Myers Squibb Company
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Celyad Oncology SA
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Dendreon Pharmaceuticals LLC
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. F. Hoffmann-La Roche Ltd.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Gilead Sciences, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. GlaxoSmithKline plc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Inovio Pharmaceuticals, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Iovance Biotherapeutics, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Johnson & Johnson Johnson & Johnson Services, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. JW CreaGene Co. Ltd
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. JW therapeutic
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Merck KGaA
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Novartis AG
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Pfizer Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Tessa Therapeutics Ltd.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
